PAXLOVID

Medical Information
New Zealand
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for New Zealand Healthcare Professionals. Would you like to proceed?

March 8, 2022

Medsafe has granted Paxlovid™ (nirmatrelvir/ritonavir tablets) provisional consent for the treatment of coronavirus disease 2019 (COVID-19) in adults 18 years of age and older, who do not require initiation of supplemental oxygen due to COVID-19 and are at increased risk of progression to hospitalisation or death.